NCT03430791 - Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 5, 2018

Primary Completion Date

May 29, 2020

Study Completion Date

January 27, 2021

Conditions

Recurrent Glioblastoma

Interventions

DRUG

Nivolumab 240 mg IV

Nivolumab IV 240mg IV every 2 weeks for maximum of 24 months.

DRUG

Nivolumab 3 mg/kg

Nivolumab IV 3mg/kg every 2 weeks for maximum of 24 months.

DRUG

Ipilimumab 1 mg/kg

Ipilimumab IV 1 mg/kg every 6 weeks for maximum of 4 doses.

DEVICE

NovoTTF200A (Optune)

A device to be worn continuously for a goal of 75% of the time, ranging from 18 hours daily nonstop or 22 hours daily with 2-3 days off monthly.

Trial Locations (1)

Miami Cancer Institute at Baptist Health, Inc., Miami